Pricing standards for combined and modified new drugs in urgent need.

To foster the R&D of a modified new drug that was suggested as one of the future drug industrial development issues, it is urgently required for the drug pricing account standards especially of the combined and modified new drugs according to a study reported by the chief researcher, Gill Young-shik of Korea United Pharmaceutical Co. during the meeting of "R&D for pharmaceutical intermediate an...